Alectos Therapeutics discovers novel treatments to block the underlying progression of neurodegenerative diseases. Alectos identifies and develops innovative strategies to address complex neurological conditions, including Alzheimer’s disease and Parkinson’s disease.
The Alectos pipeline is focused on creating new therapeutics to treat patients living with these disorders. Our GBA2 program is a disease-modifying approach to correct lysosomal dysfunction in neurodegenerative diseases, including Parkinson’s disease. This program has recently been partnered with Biogen. Our OGA program is a strategy to prevent the accumulation and spread of toxic protein aggregates in the brain. Alectos partnered with Merck to pioneer the development of the first clinical OGA inhibitor. Alectos has repatriated this program and we are applying our deep knowledge and IP to advance novel OGA inhibitors as treatments for Alzheimer’s disease, frontotemporal dementia, and ischemic stroke. We welcome partnership inquiries regarding our OGA program and our advanced preclinical development candidates.
- Drug Discovery
- Neurological Diseases
We are working On:
The Alectos pipeline is focused on creating new treatments for patients with neurological disorders, including those living with Parkinson’s and Alzheimer’s diseases. Our preclinical programs aim to identify and develop novel small molecules as potential disease-modifying therapies. Glucocerebrosidase 2 (GBA2) inhibition has emerged as a novel therapeutic strategy to enhance lysosomal function in neurodegenerative diseases. In the Alectos GBA2 program, we have identified molecules that possess drug-like properties including good potency, selectivity, pharmacokinetics, and CNS penetrance. Our lead compound, AL01811, is a selective GBA2 inhibitor with first-in-class potential as an oral disease-modifying treatment for patients with Parkinson’s disease. This program has recently been partnered with Biogen. Inhibition of O-GlcNAcase (OGA) is a promising approach for the treatment of several neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and ischemic stroke. Alectos previously partnered with Merck to advance the first clinical OGA inhibitor and OGA PET ligand to phase 1 studies, where they were found to be safe and well-tolerated. Alectos has repatriated this program and we are focused on advancing a novel OGA development candidate, enabled by our OGA PET ligand to measure target engagement in the clinic. The Alectos OGA program builds on our deep knowledge and scientific leadership in this area. We welcome partnership inquiries regarding our OGA inhibitor program and our advanced preclinical development candidates.
- Website www.alectos.com
- Phone +1 (604) 628 7129
- Email email@example.com
8999 Nelson Way
- Leadership Contact
Ernest McEachern, President & CEO